Neurocrine’s mixed schizophrenia data disappoint Wall Street – Yahoo Finance August 29, 2024 Mental Health, Mental Health and Well-being Neurocrine’s mixed schizophrenia data disappoint Wall Street Yahoo Finance Neurocrine Hammered; Can It Still Edge Into This ‘Significant Market?’ Investor’s Business Daily Neurocrine’s drug cuts schizophrenia symptoms in mid-stage study Reuters Neurocrine’s KarXT rival hits in phase 2—but… Source link
August 29, 2024 Mental Health, Mental Health and Well-being Neurocrine’s mixed schizophrenia data disappoint Wall Street Yahoo Finance Neurocrine Hammered; Can It Still Edge Into This ‘Significant Market?’ Investor’s Business Daily Neurocrine’s drug cuts schizophrenia symptoms in mid-stage study Reuters Neurocrine’s KarXT rival hits in phase 2—but… Source link